glp-1 news today 2025 november in review: breakthroughs, UPFs under fire, Novonesis advances healthy longevity GLP-1 Pharmacy Pricing Update (Dec

To help your healthcare provider, document the reaction

More recently, in March 2024, Wegovy was This approval followed promising results from novo Nordisks SELECT trial, which followed 17,604 adults with obesity or overweight and cardiovascular disease but no history of diabetes

D., Werner, U

& Kangawa, K

What new research on GLP-1s and migraines found In a 12-week study published in Headache: The Journal of Head and Face Pain , researchers tracked adults living with both obesity and chronic migraines who added the GLP-1 medication liraglutide (brand name Victoza) to their usual migraine treatment

The need is significant